KR20220167514A - Nutritional supplement for companion animal and manufacturing method thereof - Google Patents
Nutritional supplement for companion animal and manufacturing method thereof Download PDFInfo
- Publication number
- KR20220167514A KR20220167514A KR1020210076565A KR20210076565A KR20220167514A KR 20220167514 A KR20220167514 A KR 20220167514A KR 1020210076565 A KR1020210076565 A KR 1020210076565A KR 20210076565 A KR20210076565 A KR 20210076565A KR 20220167514 A KR20220167514 A KR 20220167514A
- Authority
- KR
- South Korea
- Prior art keywords
- omega
- fatty acids
- companion animals
- nutritional supplement
- present
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 48
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 47
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 47
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 44
- 235000019784 crude fat Nutrition 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 241000251468 Actinopterygii Species 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- 235000019688 fish Nutrition 0.000 description 21
- 238000000034 method Methods 0.000 description 16
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 13
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 13
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 13
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000005033 polyvinylidene chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 231100000049 endocrine disruptor Toxicity 0.000 description 1
- 239000000598 endocrine disruptor Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/22—Animal feeding-stuffs from material of animal origin from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/805—Pet food for dog, cat, bird, or fish
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Animal Husbandry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 반려동물용 영양보조제에 관한 것이다.The present invention relates to nutritional supplements for companion animals.
일반적으로, 반려동물은, 인간의 즐거움을 위한 소유물이 아니라, 반려자(친구)로서 대우하자는 의미에서 "애완 동물"로부터 순화된 말이다. 이러한 반려동물로는 반려견이나 반려고양이 등이 대표적이다.In general, a companion animal is a word tempered from "pet" in the sense of being treated as companions (friends) rather than as possessions for human enjoyment. Examples of such companion animals include companion dogs and companion cats.
우리나라에서도 반려동물을 키우며 함께 사는 인구(반려인)가 어느새 1,000만명이 넘어가고 있다. 1인 가족이 확산되고 노령인구가 늘어나면서 더욱 더 반려동물인구는 늘어날 것으로 기대된다.In Korea, the number of people (companion people) who raise companion animals and live together has already exceeded 10 million. As the single-person family spreads and the elderly population increases, the number of companion animals is expected to increase.
이와 같이 반려인이 증대됨에 따라 반려동물의 병 질환에 대한 관심도 나날이 커가고 있는 만큼 이러한 문제를 해결하기 위한 영양보조제에 대한 생산과 개발도 날로 늘어나고 있는 실정이다. 특히, 반려동물 문화의 발달로 반려동물의 수명이 많이 연장되는 상황에서 많은 반려인들이 영양보조제를 찾고 있고, 반려동물이 질병 상태에 있거나 발생 가능성이 높은 질병을 예방하기 위해 기능성 영양소가 들어 있는 영양보조제를 주식과 같이 제공하는 실정이다.In this way, as the number of companions increases, as interest in diseases of companion animals increases day by day, production and development of nutritional supplements to solve these problems are also increasing day by day. In particular, in a situation where the lifespan of companion animals is greatly extended due to the development of companion animal culture, many companions are looking for nutritional supplements, and nutritional supplements containing functional nutrients are available to prevent companion animals from suffering from diseases or diseases that are highly likely to occur. It is a situation where supplements are provided like stocks.
하지만, 기존의 반려동물용 영양보조제는, 사람이 직접 먹지 않는다는 이유 등으로 유효 영양소보다는 유당 등의 부형제를 과도하게 함유한 상태로 판매되는 문제가 있다.However, existing nutritional supplements for companion animals have a problem in that they are sold in a state that contains an excessive amount of excipients such as lactose rather than effective nutrients for the reason that people do not eat them directly.
본 발명의 기술적 과제는, 부형제의 사용 없이 높은 순도의 오메가-3 지방산을 공급할 수 있는 반려동물용 영양보조제 및 그 제조 방법을 제공하는 것이다.The technical problem of the present invention is to provide a nutritional supplement for companion animals capable of supplying high purity omega-3 fatty acids without the use of excipients and a manufacturing method thereof.
본 발명의 다른 기술적 과제는, 생선으로부터 순수한 오메가-3 지방산을 추출할 수 있는 반려동물용 영양보조제의 제조 방법을 제공하는 것이다.Another technical problem of the present invention is to provide a method for preparing a nutritional supplement for companion animals capable of extracting pure omega-3 fatty acids from fish.
본 발명의 또 다른 기술적 과제는, 오메가-3 지방산의 산패를 방지할 수 있는 반려동물용 영양보조제의 제조 방법을 제공하는 것이다.Another technical problem of the present invention is to provide a method for preparing a nutritional supplement for companion animals capable of preventing rancidity of omega-3 fatty acids.
상기 목적을 달성하기 위하여, 본 발명의 실시예에 따른 반려동물용 영양보조제는, 오메가-3 지방산을 공급하기 위한 반려동물용 영양보조제로, 오메가-3 지방산 80중량%와 나머지 조지방을 유효성분으로 함유한다.In order to achieve the above object, a nutritional supplement for companion animals according to an embodiment of the present invention is a nutritional supplement for companion animals for supplying omega-3 fatty acids, with 80% by weight of omega-3 fatty acids and the remaining crude fat as active ingredients. contain
상기 오메가-3 지방산 200mg과 상기 조지방 50mg을 하나의 캡슐 단위로 함유할 수 있다.200 mg of the omega-3 fatty acid and 50 mg of the crude fat may be contained in one capsule unit.
에이코사펜타엔산(Eicosapentaenoic acid; EPA) 120mg과 도코사헥사엔산(Docosahexaenoic acid; DHA) 80mg으로 이루어질 수 있다.It may consist of 120 mg of Eicosapentaenoic acid (EPA) and 80 mg of Docosahexaenoic acid (DHA).
상술한 본 발명의 실시예에 따른 반려동물용 영양보조제는, 상기 캡슐 단위에 2mg의 비타민E가 첨가될 수 있다.In the above-described nutritional supplement for companion animals according to an embodiment of the present invention, 2 mg of vitamin E may be added to the capsule unit.
한편, 본 발명의 다른 실시예에 따른 반려동물용 영양보조제의 제조 방법은, 생선을 준비하는 단계; 상기 준비된 생선을 세척하는 단계; 상기 세척된 생선을 탈수하는 단계; 상기 탈수된 생선을 건조하는 단계; 상기 건조된 생선으로부터 오메가-3 지방산을 추출하는 단계; 및 상기 추출된 오메가-3 지방산 200mg과 조지방 50mg을 내용물로 하여 캡슐로 감싸는 단계;를 포함한다.On the other hand, a method for manufacturing a nutritional supplement for companion animals according to another embodiment of the present invention includes preparing fish; Washing the prepared fish; Dehydrating the washed fish; drying the dehydrated fish; Extracting omega-3 fatty acids from the dried fish; and wrapping 200 mg of the extracted omega-3 fatty acids and 50 mg of crude fat into capsules.
상기 오메가-3 지방산을 추출하는 단계는, 저온 초임계 추출 방식으로 진행될 수 있다.The step of extracting the omega-3 fatty acids may be performed by a low-temperature supercritical extraction method.
상기 캡슐로 감싸는 단계에서, 상기 내용물에 2mg의 비타민E가 첨가될 수 있다.In the step of wrapping the capsule, 2 mg of vitamin E may be added to the contents.
상술한 본 발명의 다른 실시예에 따른 반려동물용 영양보조제의 제조방법은, 상기 캡슐을 폴리염화비닐리덴(PVDC; polyvinylidene chloride) 성분의 블리스터(blister)로 포장하는 단계를 더 포함할 수 있다.The method for manufacturing a nutritional supplement for companion animals according to another embodiment of the present invention described above may further include packaging the capsule in a blister of polyvinylidene chloride (PVDC) component. .
이상에서와 같이, 본 발명의 실시예에 따른 반려동물용 영양보조제 및 그 제조 방법은 다음과 같은 효과를 가질 수 있다.As described above, the nutritional supplement for companion animals and the manufacturing method according to the embodiment of the present invention may have the following effects.
본 발명의 실시예에 의하면, 오메가-3 지방산을 공급하기 위한 반려동물용 영양보조제로, 오메가-3 지방산 80중량%와 나머지 조지방을 유효성분으로 함유하는 기술구성을 제공하므로, 부형제나 착향제의 사용 없이 높은 순도의 오메가-3 지방산을 공급할 수 있다.According to an embodiment of the present invention, as a nutritional supplement for companion animals for supplying omega-3 fatty acids, since it provides a technical configuration containing 80% by weight of omega-3 fatty acids and the remaining crude fat as active ingredients, excipients or flavoring agents High purity omega-3 fatty acids can be supplied without use.
또한, 본 발명의 실시예에 의하면, 오메가-3 지방산 200mg(EPA 120mg과 DHA 80mg으로 이루어짐)과 조지방 50mg을 하나의 캡슐 단위로 함유하는 기술구성을 제공하므로, 염증 억제, 혈류 개선, 골 관절 도움, 신장 질환 유발 문제 개선, 암세포 성장 방해, 피부 질환 개선, 그리고 심장 질환 개선의 효과를 얻을 수 있었고, 구체적으로, 반려견들을 대상으로 하루 3번 식전에 위 조성의 캡슐을 매일 섭취토록 하여 관찰한 결과, 염증 반응을 완화하여 해당 질환으로 인한 증상을 개선하는데 도움이 되는 것으로 나타났고, 혈액 순환을 개선하고 혈중 지질농도를 감소시켜 심혈관계 질환에 도움이 되는 것으로 나타났고, 관절염으로 인한 염증 반응을 감소시키고 연골 분해 효소의 활성을 억제하는 등의 기전을 통해 골관절 질환에 도움이 되는 것으로 나타났고, 사구체여과율의 개선, 단백뇨의 감소 등 만성 신장질환으로 유발되는 문제들이 개선되는 것으로 나타났고, 항염증 작용과 항산화 작용을 유도하여 암세포의 성장을 방해하고 항암치료 효과를 증대 시키며 악액질(cachexia)의 예방에도 도움을 주어 생존기간연장 등 종양 치료에 도움이 되는 것으로 나타났고, 피부 질환을 개선시키는데 도움을 줄 수 있는 것으로 나타났고, 그리고 심장 질환으로 인해 발생한 염증유발 인자를 감소시키고 근육손실을 줄여 주며 생존시간을 연장시키는데 도움을 줄 수 있는 것으로 나타났다.In addition, according to an embodiment of the present invention, since it provides a technical configuration containing 200 mg of omega-3 fatty acids (consisting of 120 mg of EPA and 80 mg of DHA) and 50 mg of crude fat in one capsule unit, inflammation inhibition, blood flow improvement, and bone joint help , Improvement of kidney disease-induced problems, inhibition of cancer cell growth, improvement of skin diseases, and improvement of heart diseases were obtained. , It has been shown to help improve symptoms caused by the disease by alleviating the inflammatory response, and it has been shown to be helpful in cardiovascular disease by improving blood circulation and reducing blood lipid levels, and reducing the inflammatory response caused by arthritis It has been shown to be helpful in osteoarthritis through mechanisms such as inhibiting the activity of cartilage decomposition enzymes and inhibiting the activity of cartilage decomposition enzymes, and problems caused by chronic kidney disease, such as improvement of glomerular filtration rate and reduction of proteinuria, have been shown to be improved, and anti-inflammatory action It has been shown to be helpful in treating tumors, such as prolonging survival time, by inducing hyperoxidative action, hindering the growth of cancer cells, increasing the effectiveness of anticancer treatment, and helping to prevent cachexia. It has been shown to be able to help reduce inflammatory factors caused by heart disease, reduce muscle loss, and prolong survival time.
또한, 본 발명의 실시예에 의하면, 오메가-3 지방산을 추출하는 과정은 저온 초임계 추출 방식으로 진행되는 기술구성을 제공하므로, 열이나 화학용 매제를 배제하고 저온에서 이산화탄소만을 이용해 오일을 추출함으로 오메가-3 지방산의 원료가 되는 생선기름으로부터 헥산, 중금속, 환경 호르몬, 불필요한 불포화지방산을 깨끗하게 분리한 뒤 순수한 오메가-3 지방산을 추출할 수 있고, 궁극적으로 생체흡수율이 높은 rTG오메가-3 지방산을 얻을 수 있다.In addition, according to an embodiment of the present invention, since the process of extracting omega-3 fatty acids provides a technical configuration in which a low-temperature supercritical extraction method is performed, heat or chemical solvents are excluded and oil is extracted using only carbon dioxide at a low temperature. After cleanly separating hexane, heavy metals, environmental hormones, and unnecessary unsaturated fatty acids from fish oil, which is the raw material of omega-3 fatty acids, pure omega-3 fatty acids can be extracted, ultimately obtaining rTG omega-3 fatty acids with high bioabsorption. can
또한, 본 발명의 실시예에 의하면, 캡슐을 폴리염화비닐리덴 성분의 블리스터로 포장하는 과정을 더 포함하는 기술구성을 제공하므로, 블리스터에 의해 오메가-3 지방산으로 유입되는 수분이나 산소를 완벽하게 차단할 수 있어, 오메가-3 지방산이 수분이나 산소와 접촉할 경우 산패되면서 페록사이드(peroxide)라는 발암물질이 생성되는데 이를 완벽하게 막을 수 있다.In addition, according to an embodiment of the present invention, since a technical configuration further including a process of packaging the capsule with a blister of polyvinylidene chloride component is provided, moisture or oxygen introduced into omega-3 fatty acids by the blister is completely prevented. When omega-3 fatty acids come into contact with moisture or oxygen, they become rancid and produce carcinogens called peroxides, which can be completely blocked.
도 1은 본 발명의 일 실시예에 따른 반려동물용 영양보조제의 제조 방법을 순차적으로 나타낸 플로우차트이다.1 is a flowchart sequentially showing a method for manufacturing a nutritional supplement for companion animals according to an embodiment of the present invention.
이하, 첨부한 도면을 참고로 하여 본 발명의 실시예에 대하여 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.
도 1은 본 발명의 일 실시예에 따른 반려동물용 영양보조제의 제조 방법을 순차적으로 나타낸 플로우차트이다.1 is a flowchart sequentially showing a method for manufacturing a nutritional supplement for companion animals according to an embodiment of the present invention.
본 발명의 일 실시예에 따른 반려동물용 영양보조제는, 오메가-3 지방산을 공급하기 위한 반려동물용 영양보조제로, 오메가-3 지방산 80중량%와 나머지 조지방을 유효성분으로 함유한다.A nutritional supplement for companion animals according to an embodiment of the present invention is a nutritional supplement for companion animals for supplying omega-3 fatty acids, and contains 80% by weight of omega-3 fatty acids and the remaining crude fat as active ingredients.
본 발명에서 사용되는 "오메가-3 지방산"은 화학 구조에서 말단 메틸기로부터 3번째 탄소 원자에 이중 결합이 존재하는 것을 특징으로 하는 다불포화 지방산이다. 오메가-3 지방산은 자연에 널리 분포되어 있으며, 동물의 지질 대사에 중요한 성분이다. 이러한 오메가-3 지방산은 식물성 기름에서도 추출될 수 있지만 본 발명에서는 해양 생물(특히 생선)의 기름에서 추출된 것을 사용하였다. 나아가, 생선의 기름에서는 오메가-3 지방산으로 에이코사펜타엔산(EPA)과 도코사헥사엔산(DHA)이 추출될 수 있으며, 본 발명의 하나의 예로 사용된 오메가-3 지방산은 에이코사펜타엔산(Eicosapentaenoic acid, EPA) 120mg과 도코사헥사엔산(Docosahexaenoic acid; DHA) 80mg으로 이루어질 수 있다.The "omega-3 fatty acid" used in the present invention is a polyunsaturated fatty acid characterized by the presence of a double bond at the third carbon atom from the terminal methyl group in the chemical structure. Omega-3 fatty acids are widely distributed in nature and are important components of lipid metabolism in animals. These omega-3 fatty acids can be extracted from vegetable oil, but in the present invention, those extracted from oil of marine organisms (especially fish) were used. Furthermore, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can be extracted from fish oil as omega-3 fatty acids, and omega-3 fatty acids used as an example of the present invention are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It may consist of 120 mg of Eicosapentaenoic acid (EPA) and 80 mg of Docosahexaenoic acid (DHA).
또한, 본 발명의 실시예에 따른 반려동물용 영양보조제에서 오메가-3 지방산은 80중량%의 양으로 함유하는 것이 바람직하다. 함량이 80중량% 미만의 경우, 염증 억제, 혈류 개선, 골 관절 도움, 신장 질환 유발 문제 개선, 암세포 성장 방해, 피부 질환 개선, 그리고 심장 질환 개선의 효과를 얻을 수 없는 것으로 나타났고, 함량이 80중량%를 초과할 경우 세포막의 지질이 산화 스트레스에 취약해지는 것으로 나타났다.In addition, in the nutritional supplement for companion animals according to an embodiment of the present invention, omega-3 fatty acids are preferably contained in an amount of 80% by weight. When the content is less than 80% by weight, it has been shown that the effects of inhibiting inflammation, improving blood flow, helping bones and joints, improving kidney disease-induced problems, inhibiting cancer cell growth, improving skin diseases, and improving heart disease cannot be obtained, and the content of 80 It has been shown that lipids in cell membranes become vulnerable to oxidative stress when the weight % is exceeded.
본 발명에서 사용되는 "조지방(crude fat)"은 에테르 추출물(ether extract)이라고도 하고, 보통 속슬레 추출기를 사용해서 에테르로 지방을 추출하고 그 중량을 구해 정량한 것이다. 조지방 중에는 지방 이외에 색소(클로로필, 카로티노이드 등), 왁스, 지질, 유기산 등이 포함되어 있다. 이러한 조지방은 본 발명의 실시예에 따른 반려동물용 영양보조제의 잔부를 이룬다.The "crude fat" used in the present invention is also referred to as ether extract, and fat is usually extracted with ether using a Soxhlet extractor, and its weight is determined and quantified. Crude fat contains pigments (chlorophyll, carotenoids, etc.), wax, lipids, and organic acids in addition to fat. This crude fat forms the rest of the nutritional supplement for companion animals according to an embodiment of the present invention.
따라서, 위와 같은 구성요소가 제공되므로, 부형제나 착향제의 사용 없이 높은 순도의 오메가-3 지방산을 공급할 수 있다.Therefore, since the above components are provided, high purity omega-3 fatty acids can be supplied without using excipients or flavoring agents.
이와 더불어, 본 발명에 추가적으로 첨가되는 "비타민E"는, 오메가-3 지방산의 섭취로 인해 세포막의 지질이 산화 스트레스에 취약해지는데 이를 완화시키는 역할을 한다.In addition, "vitamin E", which is additionally added to the present invention, plays a role in alleviating the vulnerability of lipids in cell membranes to oxidative stress due to the intake of omega-3 fatty acids.
[실험예][Experimental example]
본 발명의 실시예에 따른 반려동물용 영양보조제로, 에이코사펜타엔산(EPA) 120mg, 도코사헥사엔산(DHA) 80mg, 조지방 50mg, 그리고 비타민E 2mg을 혼합하여 당업계에 공지된 통상적인 방법에 따라 캡슐 형태로 제조한 것을 실험에 사용하였다.As a nutritional supplement for companion animals according to an embodiment of the present invention, 120 mg of eicosapentaenoic acid (EPA), 80 mg of docosahexaenoic acid (DHA), 50 mg of crude fat, and 2 mg of vitamin E are mixed and conventionally known in the art. It was prepared in the form of a capsule according to the phosphorus method and used in the experiment.
이렇게 제조된 본 발명의 실시예에 따른 반려동물용 영양보조제를 반려견들을 대상으로 하루 3번 식전에 매일 섭취토록 하여 관찰한 결과는 다음과 같다.The results observed by ingesting the nutritional supplement for companion animals according to the embodiment of the present invention prepared in this way for companion dogs three times a day before meals are as follows.
1) 염증 억제1) Inhibition of inflammation
본 발명의 반려동물용 영양보조제는 내과적 질환이 있는 경우 발생하는 염증 반응을 완화하여 해당 질환으로 인한 증상을 개선하는데 도움되는 것으로 나타났다.The nutritional supplement for companion animals of the present invention has been shown to be helpful in improving the symptoms caused by the disease by alleviating the inflammatory reaction that occurs when there is an internal medical disease.
2) 혈류 개선2) Improving blood flow
본 발명의 반려동물용 영양보조제를 지속적으로 섭취하는 경우 혈액 순환을 개선하고 혈중 지질농도를 감소시켜 심혈관계 질환에 도움이 되는 것으로 나타났다.When continuously ingesting the nutritional supplement for companion animals of the present invention, it has been shown to be helpful in cardiovascular diseases by improving blood circulation and reducing blood lipid concentration.
3) 골 관절에 도움3) Helps bone joints
본 발명의 반려동물용 영양보조제는 관절염으로 인한 염증 반응을 감소시키고 연골 분해 효소의 활성을 억제하는 등의 기전을 통해 골관절 질환에 도움이 되는 것으로 나타났다.The nutritional supplement for companion animals of the present invention has been shown to be helpful for osteoarthritis through mechanisms such as reducing the inflammatory response caused by arthritis and inhibiting the activity of cartilage degrading enzymes.
4) 신장 질환 유발 문제 개선4) Improvement of problems caused by kidney disease
본 발명의 반려동물용 영양보조제를 추가적으로 급여하는 사구체여과율의 개선, 단백뇨의 감소 등 만성 신장질환으로 유발되는 문제들이 개선되는 것으로 나타났다.It was found that problems caused by chronic kidney disease, such as improvement of glomerular filtration rate and reduction of proteinuria, were improved by additionally feeding the nutritional supplement for companion animals of the present invention.
5) 암세포 성장 방해5) Interfering with cancer cell growth
본 발명의 반려동물용 영양보조제는 항염증 작용과 항산화 작용을 유도하여 암세포의 성장을 방해하고 항암치료 효과를 증대시키며 악액질(cachexia)의 예방에도 도움을 주어 생존기간연장 등 종양 치료에 도움이 되는 것으로 나타났다.The nutritional supplement for companion animals of the present invention inhibits the growth of cancer cells by inducing anti-inflammatory and antioxidant effects, increases the anti-cancer treatment effect, and helps to prevent cachexia, which is helpful in tumor treatment such as prolonging survival time. appeared to be
6) 피부 질환 개선6) Improve skin disease
다중불포화지방산은 피부의 구조와 기능을 유지하기 위해 필수적인 중요한 영양소입니다. 본 발명의 반려동물용 영양보조제의 경우 염증완화와 피부 질환을 개선시키는데 도움을 줄 수 있는 것으로 나타났다.Polyunsaturated fatty acids are important nutrients essential for maintaining the structure and function of the skin. In the case of the nutritional supplement for companion animals of the present invention, it has been shown that it can help relieve inflammation and improve skin diseases.
7) 심장 질환에 도움7) Helps with Heart Disease
본 발명의 반려동물용 영양보조제의 충분한 공급은 심장 질환으로 인해 발생한 염증유발 인자를 감소시키고 근육손실을 줄여 주며 생존시간을 연장키는데 도움을 줄 수 있는 것으로 나타났다.It has been shown that sufficient supply of the nutritional supplement for companion animals of the present invention can help reduce inflammatory factors caused by heart disease, reduce muscle loss, and prolong survival time.
이하, 도 1을 참조하여, 본 발명의 다른 실시예에 따른 반려동물용 영양보조제의 제조 방법에 대해 설명한다.Hereinafter, with reference to FIG. 1, a method for manufacturing a nutritional supplement for companion animals according to another embodiment of the present invention will be described.
본 발명의 다른 실시예에 따른 반려동물용 영양보조제의 제조 방법, 도 1에 도시된 바와 같이, 먼저 생선(어류)을 준비한다(S110). 이때, 중금속 위험이 적은 소형 어류를 준비한다. 즉, 멸치, 정어리 같은 소형 어류는 플랑크톤을 주로 섭취하는 먹이사슬 최하위에 위치하여 중금속 등의 해양 오염으로부터 안전하기 때문에 하위 어종을 정제하여 안전하고 깨끗한 오메가-3 지방산을 만들기에 적합할 수 있다.As shown in FIG. 1, a method for manufacturing a nutritional supplement for companion animals according to another embodiment of the present invention, fish (fish) is first prepared (S110). At this time, prepare small fish with low risk of heavy metals. That is, small fish such as anchovies and sardines are located at the bottom of the food chain mainly ingesting plankton and are safe from marine pollution such as heavy metals.
이러한 준비된 생선을 불순물이 없도록 세척하고(S120), 이후 생선에서 수분이 제거되도록 생선을 탈수한다(S130). 그리고 나서, 탈수된 생선을 건조한다(S140). 건조과정(S140)에서의 생선의 함수율을 5 내지 10% 내외로 관리하는 것이 바람직하다. 함수율이 10%을 초과하면, 후술하는 추출과정(S150)에서 오메가-3 지방산의 추출이 용이하지 않는 문제가 있다.The prepared fish is washed to remove impurities (S120), and then the fish is dehydrated to remove moisture from the fish (S130). Then, the dehydrated fish is dried (S140). It is preferable to manage the water content of fish in the drying process (S140) to around 5 to 10%. If the moisture content exceeds 10%, there is a problem in that it is not easy to extract omega-3 fatty acids in the extraction process (S150) described later.
이후, 건조된 생선으로부터 오메가-3 지방산(EPA와 DHA)을 추출한다(S150). 나아가, 오메가-3 지방산을 추출하는 과정은 저온 초임계 추출 방식으로 진행될 수 있다. 따라서, 열이나 화학용 매제를 배제하고 저온에서 이산화탄소만을 이용해 오일을 추출함으로 오메가-3 지방산의 원료가 되는 생선기름으로부터 헥산, 중금속, 환경 호르몬, 불필요한 불포화지방산을 깨끗하게 분리한 뒤 순수한 오메가-3 지방산을 추출할 수 있고, 궁극적으로 생체흡수율이 높은 rTG오메가-3 지방산을 얻을 수 있다.Then, omega-3 fatty acids (EPA and DHA) are extracted from the dried fish (S150). Furthermore, the process of extracting omega-3 fatty acids may be performed by a low-temperature supercritical extraction method. Therefore, by excluding heat or chemical solvents and extracting oil using only carbon dioxide at low temperature, hexane, heavy metals, endocrine disruptors, and unnecessary unsaturated fatty acids are clearly separated from fish oil, which is the raw material of omega-3 fatty acids, and pure omega-3 fatty acids can be extracted, and ultimately rTG omega-3 fatty acids with high bioabsorption can be obtained.
그리고 나서, 이렇게 추출된 오메가-3 지방산 200mg (이는 EPA 120mg과 DHA 80mg으로 이루어짐), 미리 준비한 조지방 50mg, 그리고 비타민E 2mg을 내용물로 하여 캡슐로 감싼다(S160). 예를 들어, 캡슐은 반려견에게 급여하기 좋은 작은 연질캡슐로 약 1cm(5 oval)의 크기를 가지는 것이 바람직할 수 있다.Then, 200 mg of omega-3 fatty acids thus extracted (which consists of 120 mg of EPA and 80 mg of DHA), 50 mg of crude fat prepared in advance, and 2 mg of vitamin E are wrapped in capsules (S160). For example, the capsule may preferably have a size of about 1 cm (5 oval) as a small soft capsule suitable for feeding to companion dogs.
이와 더불어, 본 발명의 다른 실시예에 따른 반려동물용 영양보조제의 제조 방법은, 캡슐을 폴리염화비닐리덴(PVDC; polyvinylidene chloride) 성분의 블리스터(blister)로 포장하는 과정을 더 포함할 수 있다(S170). 따라서, 블리스터에 의해 오메가-3 지방산으로 유입되는 수분이나 산소를 완벽하게 차단할 수 있어, 오메가-3 지방산이 수분이나 산소와 접촉할 경우 산패되면서 페록사이드(peroxide)라는 발암물질이 생성되는데 이를 완벽하게 막을 수 있다.In addition, the method of manufacturing a nutritional supplement for companion animals according to another embodiment of the present invention may further include a process of packaging the capsule in a blister of polyvinylidene chloride (PVDC) component. (S170). Therefore, it is possible to completely block moisture or oxygen from flowing into omega-3 fatty acids by the blisters, and when omega-3 fatty acids come in contact with moisture or oxygen, they become rancid and produce carcinogens called peroxides. can be prevented
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concept of the present invention defined in the following claims are also made according to the present invention. falls within the scope of the rights of
S110: 생선 준비
S120: 생선 세척
S130: 생선 탈수
S140: 생선 건조
S150: 오메가-3 지방산 추출
S160: 캡슐화
S170: 블리스터 포장S110: Preparing fish S120: Washing fish
S130: Fish dewatering S140: Fish drying
S150: Omega-3 Fatty Acid Extraction S160: Encapsulation
S170: Blister packaging
Claims (3)
오메가-3 지방산 80중량%와 나머지 조지방을 유효성분으로 함유하는
반려동물용 영양보조제.As a nutritional supplement for companion animals to supply omega-3 fatty acids,
Contains 80% by weight of omega-3 fatty acids and the remaining crude fat as active ingredients
Nutritional supplements for companion animals.
상기 오메가-3 지방산 200mg과 상기 조지방 50mg을 하나의 캡슐 단위로 함유하는
반려동물용 영양보조제.In paragraph 1,
Containing 200 mg of the omega-3 fatty acids and 50 mg of the crude fat in one capsule unit
Nutritional supplements for companion animals.
생선을 준비하는 단계;
상기 준비된 생선을 세척하는 단계;
상기 세척된 생선을 탈수하는 단계;
상기 탈수된 생선을 건조하는 단계;
상기 건조된 생선으로부터 오메가-3 지방산을 추출하는 단계; 및
상기 추출된 오메가-3 지방산 200mg과 조지방 50mg을 캡슐로 감싸는 단계;
를 포함하는
반려동물용 영양보조제의 제조 방법.As a manufacturing method of the nutritional supplement for companion animals of claim 2,
preparing fish;
Washing the prepared fish;
Dehydrating the washed fish;
drying the dehydrated fish;
Extracting omega-3 fatty acids from the dried fish; and
Wrapping 200 mg of the extracted omega-3 fatty acids and 50 mg of crude fat in a capsule;
containing
Manufacturing method of nutritional supplements for companion animals.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210076565A KR20220167514A (en) | 2021-06-14 | 2021-06-14 | Nutritional supplement for companion animal and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210076565A KR20220167514A (en) | 2021-06-14 | 2021-06-14 | Nutritional supplement for companion animal and manufacturing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220167514A true KR20220167514A (en) | 2022-12-21 |
Family
ID=84536885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210076565A KR20220167514A (en) | 2021-06-14 | 2021-06-14 | Nutritional supplement for companion animal and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220167514A (en) |
-
2021
- 2021-06-14 KR KR1020210076565A patent/KR20220167514A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009354456B2 (en) | Solvent-free process for obtaining phospholipids and neutral enriched krill oils | |
| Koshio et al. | Effects of oxidized herring and canola oils in diets on growth, survival, and flavor of Atlantic salmon, Salmo salar | |
| US8784921B2 (en) | Method for concentrating lipids | |
| Maqsood et al. | Extraction, processing, and stabilization of health-promoting fish oils | |
| Rizliya et al. | Biological, physical, and chemical properties of fish oil and industrial applications | |
| Nath et al. | Dietary supplementation with the microalgae Parietochloris incisa increases survival and stress resistance in guppy (Poecilia reticulata) fry | |
| Chen et al. | Two filamentous microalgae as feed ingredients improved flesh quality and enhanced antioxidant capacity and immunity of the gibel carp (Carassius auratus gibelio) | |
| WO2010149662A1 (en) | Composition comprising omega-7 and/or omega-4 fatty acids | |
| CA2643906A1 (en) | A non marine or non algal sourced omega 3 feed/food supplement and process for stabilizing, enhancing the conversion efficiency, and enrichment of omega 3 fatty acids in livestock/humans and products therefrom | |
| Al-Khalifa | Production of added-value poultry meat: enrichment with n-3 polyunsaturated fatty acids | |
| WO2013149384A1 (en) | Brain atrophy prevention agent | |
| Aryee et al. | Perspectives on preserving lipid quality and strategies for value enhancement | |
| US20070218182A1 (en) | Novel Fat Powders | |
| Li et al. | Effects of vitamin C deficiency or excess on growth performance, anti-oxidative response and fatty acid composition of juvenile abalone Haliotis discus hannai Ino | |
| Carvalho et al. | Valorization of lipid by-products | |
| KR20220167514A (en) | Nutritional supplement for companion animal and manufacturing method thereof | |
| Mizambwa | Effects of replacing fish oil with microalgae biomass (Schizochytrium spp) as a source of n-3 LC-PUFA to Atlantic salmon (Salmo salar) on growth performance, fillet quality and fatty acid composition | |
| JP6180485B2 (en) | Oil compositions, formulations containing oil compositions, and their use to prevent or treat obesity-related diseases and disorders by reducing the accumulation of built-in fats and improving glucose tolerance | |
| JPH02113850A (en) | Oils and fats composition for carcinogenesis inhibition | |
| KR102333548B1 (en) | Animal feed composition comprising bass extract and preparation method thereof | |
| Uçak et al. | Products based on omega-3 polyunsaturated fatty acids and health effects | |
| Kerry et al. | Physical and chemical properties of lipid by-products from seafood waste | |
| Zanqui et al. | Multivariate study of Nile tilapia byproducts enriched with omega-3 and dried with different methods | |
| Selim et al. | Response of growing rabbits to dietary antioxidant vitamins E and C. 2. Effect on meat quality | |
| KR100861943B1 (en) | Feed for fishes for conversion cla into lipid components of fish and for improvement of growth ratio of fishes, and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal |